Starting from 1 June 2024, Kalydeco (ivacaftor) will be available on the Pharmaceutical Benefits Scheme (PBS) for patients aged 4 months and older with certain CFTR mutations. This is a major step forward for the cystic fibrosis community in Australia!
Who’s Eligible?
- Patients aged 4 months or older with a G551D or other gating (Class III) mutation on the CFTR gene.
- Patients aged 4 months or older with at least one non-gating mutation on the CFTR gene that is responsive to ivacaftor potentiation based on clinical or in vitro data.
With this reimbursement, approximately 95 people with cystic fibrosis will have access to a CFTR modulator for the first time. This milestone offers new hope and improved treatment options for those affected by CF in Australia.
For more information, follow the link: https://bit.ly/3R6Ad9C